$DYAI
Dyadic International Inc

2022 Q3 Form 10-Q Financial Statement

#000143774922019789 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $879.6K $658.6K $648.4M
YoY Change 26.94% -29.72% 40.8%
Cost Of Revenue $602.8K $411.1K $404.7M
YoY Change 53.57% -50.44% 3.58%
Gross Profit $276.8K $247.4K $243.7M
YoY Change -7.87% 129.99% 249.32%
Gross Profit Margin 31.46% 37.57% 37.58%
Selling, General & Admin $1.383M $1.714M $1.656M
YoY Change -18.28% -1.92% 6.82%
% of Gross Profit 499.88% 692.69% 0.68%
Research & Development $743.6K $1.831M $1.343B
YoY Change -60.9% -17.13% -25.73%
% of Gross Profit 268.68% 739.88% 551.07%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $743.6K $1.831M $1.343B
YoY Change -60.9% -17.13% -25.73%
Operating Profit -$1.863M -$3.318M -$2.745B
YoY Change -43.94% -14.2% -17.35%
Interest Expense $54.30K $30.01K $2.968M
YoY Change 1595.82% 43.58% -88.44%
% of Operating Profit
Other Income/Expense, Net $54.30K $30.01K $253.0M
YoY Change -96.62% 43.58% 885.46%
Pretax Income -$1.809M -$3.288M -$2.492M
YoY Change 5.47% -14.51% -24.27%
Income Tax
% Of Pretax Income
Net Earnings -$1.809M -$3.288M -$2.492M
YoY Change 5.47% -14.51% -24.38%
Net Earnings / Revenue -205.68% -499.28% -0.38%
Basic Earnings Per Share -$0.06 -$0.12 -$0.09
Diluted Earnings Per Share -$63.72K -$116.3K -$88.20K
COMMON SHARES
Basic Shares Outstanding 28.42M 28.26M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.20M $15.64M $15.44M
YoY Change -37.57% -38.91% -43.3%
Cash & Equivalents $6.739M $9.476M $12.42B
Short-Term Investments $7.462M $6.164M $3.021M
Other Short-Term Assets $448.2K $104.8K $244.2K
YoY Change -21.36% 3.91% 10.99%
Inventory
Prepaid Expenses
Receivables $235.4K $1.145M $528.2M
Other Receivables $43.87K $42.24K $28.90K
Total Short-Term Assets $14.93M $16.93M $16.24B
YoY Change -36.67% -35.26% 57922.59%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $284.7K $284.7K $2.283M
YoY Change 0.0% 0.0% 715.3%
Other Assets $6.003K $6.024K $6.104M
YoY Change -2.28% -2.4% 99135.9%
Total Long-Term Assets $290.7K $290.7K $2.289B
YoY Change -0.05% -0.05% 786853.52%
TOTAL ASSETS
Total Short-Term Assets $14.93M $16.93M $16.24B
Total Long-Term Assets $290.7K $290.7K $2.289B
Total Assets $15.22M $17.22M $18.53B
YoY Change -36.22% -34.88% 65419.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $777.2K $1.095M $866.3M
YoY Change -18.85% -55.02% 58680.93%
Accrued Expenses $987.9K $1.224M $533.0M
YoY Change 17.26% 105.84% 191858.38%
Deferred Revenue $445.0K $901.3K $315.0M
YoY Change 173.57% 248.34% 37300.62%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.387M $3.397M $1.826B
YoY Change 21.59% 3.31% 70319.08%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $220.6K $264.7K $308.8K
YoY Change
Total Long-Term Liabilities $220.6K $264.7K $308.8K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.387M $3.397M $1.826B
Total Long-Term Liabilities $220.6K $264.7K $308.8K
Total Liabilities $2.607M $3.662M $2.135B
YoY Change 32.82% 11.36% 82344.13%
SHAREHOLDERS EQUITY
Retained Earnings -$71.34M -$69.53M -$66.24B
YoY Change 19.83% 20.25% 122628.69%
Common Stock $40.72K $40.52K $40.52M
YoY Change 0.95% 0.46% 101683.56%
Preferred Stock
YoY Change
Treasury Stock (at cost) $18.93M $18.93M $18.93B
YoY Change 0.16% 0.16% 100058.28%
Treasury Stock Shares
Shareholders Equity $12.61M $13.56M $16.39M
YoY Change
Total Liabilities & Shareholders Equity $15.22M $17.22M $18.53B
YoY Change -36.22% -34.88% 65419.07%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.809M -$3.288M -$2.492M
YoY Change 5.47% -14.51% -24.38%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.776M -$1.775M -$2.850B
YoY Change -59.02% -25.96% 49.51%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$1.310M -$1.156M -$520.9K
YoY Change -132.7% -146.33% -90.99%
Cash From Investing Activities -$1.310M -$1.156M -$520.9M
YoY Change -132.7% -146.33% -90.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 359.7K 0.000 $42.35M
YoY Change -61072.88% -100.0% -63.43%
NET CHANGE
Cash From Operating Activities -1.776M -1.775M -$2.850B
Cash From Investing Activities -1.310M -1.156M -$520.9M
Cash From Financing Activities 359.7K 0.000 $42.35M
Net Change In Cash -2.726M -2.932M -$3.329B
YoY Change 728.29% -404.0% -56.08%
FREE CASH FLOW
Cash From Operating Activities -$1.776M -$1.775M -$2.850B
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40517659
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40482659
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28264157
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28229157
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
12253502
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2021 dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5605040
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4799215
CY2021 dyai Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
0 usd
CY2017Q2 dyai Collaborative Arrangement Payment For Research And Development Agreement
CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
1000000.0 eur
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55264
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0486747
dei Entity Address Address Line1
EntityAddressAddressLine1
140 Intracoastal Pointe Drive, Suite 404
dei Entity Address City Or Town
EntityAddressCityOrTown
Jupiter
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33477
dei City Area Code
CityAreaCode
561
dei Local Phone Number
LocalPhoneNumber
743-8333
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1224338 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
709560 usd
CY2022Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
901331 usd
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
DYAI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28423100
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9476412 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15748480 usd
CY2022Q2 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
6163833 usd
CY2021Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
4511780 usd
CY2022Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
42237 usd
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
94375 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1145451 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
277831 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
104831 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
375830 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
16932764 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
21008296 usd
CY2022Q2 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 usd
CY2021Q4 dyai Prepaid Research And Development In Process Current
PrepaidResearchAndDevelopmentInProcessCurrent
284709 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6024 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6117 usd
CY2022Q2 us-gaap Assets
Assets
17223497 usd
CY2021Q4 us-gaap Assets
Assets
21299122 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1095208 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1547953 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
151147 usd
CY2022Q2 dyai Deferred License Revenue Current
DeferredLicenseRevenueCurrent
176471 usd
CY2021Q4 dyai Deferred License Revenue Current
DeferredLicenseRevenueCurrent
147059 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3397348 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2555719 usd
CY2022Q2 dyai Deferred License Revenue Net Of Current Portion
DeferredLicenseRevenueNetOfCurrentPortion
264706 usd
CY2021Q4 dyai Deferred License Revenue Net Of Current Portion
DeferredLicenseRevenueNetOfCurrentPortion
352941 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
46570 usd
CY2022Q2 us-gaap Liabilities
Liabilities
3662054 usd
CY2021Q4 us-gaap Liabilities
Liabilities
2908660 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
40518 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
40483 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101977102 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101026496 usd
CY2022Q2 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
18929915 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69526262 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-63746602 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13561443 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18390462 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17223497 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21299122 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
658553 usd
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
937092 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1306980 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1397612 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
411109 usd
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
829504 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
815855 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1220266 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1830798 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2209242 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3173660 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4017340 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1714029 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1747614 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3369729 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3301621 usd
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-20621 usd
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-17806 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-10373 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-46078 usd
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
3976557 usd
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
4804166 usd
us-gaap Costs And Expenses
CostsAndExpenses
7369617 usd
us-gaap Costs And Expenses
CostsAndExpenses
8585305 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3318004 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3867074 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6062637 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-7187693 usd
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
30009 usd
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
20900 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
32977 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
46570 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
250000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
30009 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20900 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
282977 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3287995 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3846174 usd
us-gaap Net Income Loss
NetIncomeLoss
-5779660 usd
us-gaap Net Income Loss
NetIncomeLoss
-7141123 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
28264157
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
27645366
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
28257776
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
27589627
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
18390462 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
453791 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42350 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2491665 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
16394938 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
454500 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3287995 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13561443 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
28446561 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
421071 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
115800 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3294949 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
25688483 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
446120 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
870340 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3846174 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
23158769 usd
us-gaap Net Income Loss
NetIncomeLoss
-5779660 usd
us-gaap Net Income Loss
NetIncomeLoss
-7141123 usd
us-gaap Share Based Compensation
ShareBasedCompensation
908291 usd
us-gaap Share Based Compensation
ShareBasedCompensation
867191 usd
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
25217 usd
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
159481 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10372 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-46079 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-52138 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
51066 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
890686 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
36049 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-273288 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-179617 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-430899 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1427809 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
514778 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
104546 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
750184 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
135732 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-58823 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4625800 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4307783 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
6177270 usd
us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
11283940 usd
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
4500000 usd
us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
8000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1677270 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3283940 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
42350 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
986140 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42350 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
986140 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-11348 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-12636 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6272068 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6618219 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15748480 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20637045 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9476412 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14018826 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em>, the Company's revenue was generated from seven and eleven customers, respectively. For the <em style="font: inherit;">six</em> months ended <em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em>, the Company’s revenue was generate<span style="background-color:#ffffff;">d from eleven and thirteen customers, respectively. As of </span><em style="font: inherit;"> June 30, 2022</em><span style="background-color:#ffffff;"> and </span><em style="font: inherit;"> December 31, 2021</em><span style="background-color:#ffffff;">, the Company’s accounts receivable was from nine</span><span style="background-color:#ffffff;"> and eight customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><span style="background-color:#ffffff;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the <em style="font: inherit;">three</em> months ended </span><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em><span style="background-color:#ffffff;">, the Company had </span>four<span style="background-color:#ffffff;"> and </span>six<span style="background-color:#ffffff;"> customers outside of the United States (i.e., European and Asian customers) that accounted for approximately </span>$239,000<span style="background-color:#ffffff;"> or </span>38.9%<span style="background-color:#ffffff;"> and </span>$797,000<span style="background-color:#ffffff;"> or </span>85.1%<span style="background-color:#ffffff;"> of the revenue, respectively. For the </span><em style="font: inherit;">six</em><span style="background-color:#ffffff;"> months ended </span><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em><span style="background-color:#ffffff;">, the Company had </span>five<span style="background-color:#ffffff;"> and </span>seven<span style="background-color:#ffffff;"> customers outside of the United States that accounted for approximately </span>$375,000<span style="background-color:#ffffff;"> or </span>32.7%<span style="background-color:#ffffff;"> and </span>$1,121,000<span style="background-color:#ffffff;"> or </span>80.2%<span style="background-color:#ffffff;"> of the revenue, respectively. </span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> June 30, 2022</em><span style="background-color:#ffffff;">, the Company had </span>five<span style="background-color:#ffffff;"> customers outside of the United States (i.e., European and Asian customers) that accounted for approximately </span>$179,000<span style="background-color:#ffffff;"> or </span>15.6%<span style="background-color:#ffffff;"> of accounts receivable. As of </span><em style="font: inherit;"> December 31, 2021</em><span style="background-color:#ffffff;">, the Company had four customers outside of the United States that accounted for approximately </span>$157,000<span style="background-color:#ffffff;"> or </span>56.4%<span style="background-color:#ffffff;"> of accounts receivable.</span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the <em style="font: inherit;">three</em> months ended </span><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em><span style="background-color:#ffffff;">, </span>two<span style="background-color:#ffffff;"> </span><span style="background-color:#ffffff;">CROs accounted for approximately </span>$1,299,000<span style="background-color:#ffffff;"> or </span>96.2%<span style="background-color:#ffffff;"> and </span>$2,622,000<span style="background-color:#ffffff;"> or </span>95.8%<span style="background-color:#ffffff;"> of total research services we purchased, respectively. For the <em style="font: inherit;">six</em> months ended </span><em style="font: inherit;"> June 30, 2022 </em>and <em style="font: inherit;">2021</em><span style="background-color:#ffffff;">, </span>two<span style="background-color:#ffffff;"> and </span>three<span style="background-color:#ffffff;"> CROs accounted for approximately $2,794,000 </span><span style="background-color:#ffffff;">or 96.5% </span><span style="background-color:#ffffff;">and </span>$4,639,000<span style="background-color:#ffffff;"> or </span>96.8%<span style="background-color:#ffffff;"> of total research services we purchased, respectively. As of </span><em style="font: inherit;"> June 30, 2022</em><span style="background-color:#ffffff;"> and </span><em style="font: inherit;"> December 31, 2021</em><span style="background-color:#ffffff;">, two CROs accounted for approximately </span>$873,000<span style="background-color:#ffffff;"> or </span>79.7%<span style="background-color:#ffffff;"> and approximately $1,312,000 or 84.8% of the accounts payable, respectively. The loss of <em style="font: inherit;">one</em> CRO or a combination of the Company’s CROs could adversely affect its operations.</span></p>
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
69464 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
45839 usd
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
29518 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
326712 usd
CY2022Q2 dyai Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
5564 usd
CY2021Q4 dyai Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
0 usd
CY2022Q2 us-gaap Prepaid Taxes
PrepaidTaxes
285 usd
CY2021Q4 us-gaap Prepaid Taxes
PrepaidTaxes
3279 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
104831 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
375830 usd
CY2022Q2 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
896760 usd
CY2021Q4 dyai Research And Development In Process Current
ResearchAndDevelopmentInProcessCurrent
1363889 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
95597 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27675 usd
CY2022Q2 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
102851 usd
CY2021Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
156389 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1095208 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1547953 usd
CY2022Q2 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
833517 usd
CY2021Q4 dyai Accrued Research And Development In Process Current
AccruedResearchAndDevelopmentInProcessCurrent
194250 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
309203 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
405758 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
81618 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
109552 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1224338 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
709560 usd
CY2022Q2 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
1616605000 usd
CY2021Q2 dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
2036753000 usd
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
2752161000 usd
dyai Research And Development Expense Outside Contracted Services
ResearchAndDevelopmentExpenseOutsideContractedServices
3695947000 usd
CY2022Q2 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
199475000 usd
CY2021Q2 dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
149587000 usd
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
406265000 usd
dyai Research And Development Expense Personnel Related Costs
ResearchAndDevelopmentExpensePersonnelRelatedCosts
297749000 usd
CY2022Q2 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
14718000 usd
CY2021Q2 dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
22902000 usd
dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
15234000 usd
dyai Research And Development Expense Facilities Overhead And Other
ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther
23644000 usd
CY2022Q2 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
1830798000 usd
CY2021Q2 dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
2209242000 usd
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
3173660000 usd
dyai Research And Development Expense Including Related Party
ResearchAndDevelopmentExpenseIncludingRelatedParty
4017340000 usd
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
15700000 usd
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
13100000 usd
dyai Deferred Tax Assets Valuation Allowance Coverage Percent
DeferredTaxAssetsValuationAllowanceCoveragePercent
1 pure
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5605040
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4799215
CY2022Q2 us-gaap Cash
Cash
1521964 usd
CY2022Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
7954448 usd
CY2022Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9476412 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9476412 usd
CY2022Q2 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
15588243 usd
CY2022Q2 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
52002 usd
CY2022Q2 us-gaap Investments And Cash
InvestmentsAndCash
15640245 usd
CY2021Q4 us-gaap Cash
Cash
1377094 usd
CY2021Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
14371386 usd
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
15748480 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15748480 usd
CY2021Q4 dyai Cash Cash Equivalents And Investments Fair Value
CashCashEquivalentsAndInvestmentsFairValue
20257765 usd
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
2495 usd
CY2021Q4 us-gaap Investments And Cash
InvestmentsAndCash
20260260 usd
CY2021Q4 dyai Upfront Payment Payable
UpfrontPaymentPayable
500000 usd
CY2021Q4 dyai Number Of Performance Obligations
NumberOfPerformanceObligations
2 pure
CY2017Q2 dyai Collaborative Arrangement Payment For Research And Development Agreement
CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
1100000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4774215
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.04
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M20D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8413444 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
865825
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.43
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
35000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
30000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.87
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75000
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.81
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5500040
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.23
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4113421 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4070223
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M26D
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3937808 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
454500 usd
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
446120 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
908291 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
867191 usd
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001

Files In Submission

Name View Source Status
0001437749-22-019789-index-headers.html Edgar Link pending
0001437749-22-019789-index.html Edgar Link pending
0001437749-22-019789.txt Edgar Link pending
0001437749-22-019789-xbrl.zip Edgar Link pending
dyai-20200930_g1copy.jpg Edgar Link pending
dyai-20220630.xsd Edgar Link pending
dyai20220630_10q.htm Edgar Link pending
ex_379148.htm Edgar Link pending
ex_379149.htm Edgar Link pending
ex_379150.htm Edgar Link pending
ex_379151.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
dyai-20220630_cal.xml Edgar Link unprocessable
dyai-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dyai-20220630_pre.xml Edgar Link unprocessable
dyai20220630_10q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dyai-20220630_def.xml Edgar Link unprocessable